"Melanoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)
| Descriptor ID |
D008545
|
| MeSH Number(s) |
C04.557.465.625.650.510 C04.557.580.625.650.510 C04.557.665.510
|
| Concept/Terms |
Melanoma- Melanoma
- Melanomas
- Malignant Melanoma
- Malignant Melanomas
- Melanoma, Malignant
- Melanomas, Malignant
|
Below are MeSH descriptors whose meaning is more general than "Melanoma".
Below are MeSH descriptors whose meaning is more specific than "Melanoma".
This graph shows the total number of publications written about "Melanoma" by people in this website by year, and whether "Melanoma" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 4 | 1 | 5 |
| 1996 | 11 | 2 | 13 |
| 1997 | 8 | 0 | 8 |
| 1998 | 10 | 0 | 10 |
| 1999 | 9 | 1 | 10 |
| 2000 | 14 | 1 | 15 |
| 2001 | 13 | 3 | 16 |
| 2002 | 18 | 3 | 21 |
| 2003 | 15 | 2 | 17 |
| 2004 | 14 | 2 | 16 |
| 2005 | 16 | 2 | 18 |
| 2006 | 30 | 2 | 32 |
| 2007 | 22 | 1 | 23 |
| 2008 | 28 | 5 | 33 |
| 2009 | 29 | 3 | 32 |
| 2010 | 24 | 5 | 29 |
| 2011 | 41 | 4 | 45 |
| 2012 | 33 | 3 | 36 |
| 2013 | 34 | 6 | 40 |
| 2014 | 37 | 5 | 42 |
| 2015 | 35 | 0 | 35 |
| 2016 | 26 | 0 | 26 |
| 2017 | 53 | 0 | 53 |
| 2018 | 29 | 1 | 30 |
| 2019 | 44 | 1 | 45 |
| 2020 | 36 | 6 | 42 |
| 2021 | 27 | 1 | 28 |
| 2022 | 33 | 0 | 33 |
| 2023 | 35 | 0 | 35 |
| 2024 | 27 | 5 | 32 |
| 2025 | 10 | 1 | 11 |
To return to the timeline,
click here.
Below are the most recent publications written about "Melanoma" by people in Profiles.
-
Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy. Nature. 2025 Oct; 646(8084):462-473.
-
Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade-resistant melanoma: Final analysis from a phase 1b study. Cancer. 2025 Aug 01; 131(15):e70022.
-
Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma. Clin Cancer Res. 2025 Aug 01; 31(15):3249-3258.
-
Combinatorial therapy regimens targeting preclinical models of melanoma resistant to immune checkpoint blockade. J Clin Invest. 2025 Sep 16; 135(18).
-
Comparison of Patients With Observed High-Risk Choroidal Nevi That Evolved into Melanomas vs Patients with Immediately Treated Uveal Melanomas. Am J Ophthalmol. 2025 Oct; 278:328-336.
-
IL-2-independent expansion, persistence, and antitumor activity in TIL expressing regulatable membrane-bound IL-15. Mol Ther. 2025 Aug 06; 33(8):3605-3623.
-
Transcriptomic signatures in peripheral CD4+T-lymphocytes may reflect melanoma staging and immunotherapy responsiveness prior to ICI initiation. Front Immunol. 2025; 16:1529707.
-
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 study. Eur J Cancer. 2025 May 02; 220:115381.
-
Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76?K trial. Eur J Cancer. 2025 May 02; 220:115371.
-
The potential impact of ACOG guideline changes on genital melanoma detection rates in females: a retrospective cross-sectional analysis and implications for clinical practice. Arch Dermatol Res. 2025 Feb 19; 317(1):438.